ResMed Inc (RMD)
198.46
+0.80 (+0.40%)
USD |
NYSE |
May 23, 16:00
198.50
+0.04 (+0.02%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 29.03B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -1.13% |
| Valuation | |
| PE Ratio | 37.37 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 8.235 |
| Price to Book Value | 8.854 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.42 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2076 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 35.26% |
News
Headline
Wire
Time (ET)
Yahoo
05/21 09:43
Globe Newswire
05/18 16:05
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 08/05/2022* | -- | Results | Q4 2022 | -- | 1.45 | -- | |
| 08/05/2022* | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 04/28/2022 | -- | Results | Q3 2022 | 1.32 | 1.44 | -8.13% | |
| 04/28/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 01/27/2022 | -- | Results | Q2 2022 | 1.47 | 1.52 | -3.50% | |
| 01/27/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 10/28/2021 | -- | Results | Q1 2022 | 1.51 | 1.35 | 11.69% | |
| 10/28/2021 | 16:30 EST | Earnings Call | Q1 2022 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting. |
| URL | https://www.resmed.com |
| Investor Relations URL | https://investors.resmed.com/investor-relations/default.aspx |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Aug. 05, 2022 (est.) |
| Last Earnings Release | Apr. 28, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 11, 2022 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 1.65 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.6388 |
| Yield to Sector | 0.4405 |
| Yield to Industry | 1.091 |
| Last Dividend Amt. | 0.42 |
| Dividend Frequency | Quarterly |
| Last Ex-Dividend Date | May. 11, 2022 |
| Yield (TTM) | 0.85% |
| Forward Yield | 0.85% |
| Payout Ratio | 30.87% |
| Cash Payout Ratio | 70.02% |
| Consistent Payer (5Y) |
|
| Consistent Growth (5Y) |
|
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of May 23, 2022.
Fundamentals
| Revenue (TTM) | 3.539B |
| Total Expenses (TTM) | 2.553B |
| Net Income (TTM) | 779.48M |
| Total Assets (Quarterly) | 4.905B |
| Total Liabilities (Quarterly) | 1.626B |
| Shareholders Equity (Quarterly) | 3.279B |
| Cash from Operations (TTM) | 498.19M |
| Cash from Investing (TTM) | -222.75M |
| Cash from Financing (TTM) | -299.90M |
Ratings
Profile
Edit
| ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting. |
| URL | https://www.resmed.com |
| Investor Relations URL | https://investors.resmed.com/investor-relations/default.aspx |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Aug. 05, 2022 (est.) |
| Last Earnings Release | Apr. 28, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 11, 2022 |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| TMFM | 9.264M USD | 4.42% |
| FSMEX | 363.76M USD | 4.03% |
| WCMRX | 1.027B USD | 3.58% |
| IHI | 188.98M USD | 2.71% |
| INGFX | 241.35M USD | 2.36% |
| BMEZ | 47.72M USD | 1.89% |
| FIGSX | 268.22M USD | 1.84% |
| FSPHX | 116.40M USD | 1.25% |
| VMGIX | 197.40M USD | 0.99% |
| VOT | 197.40M USD | 0.99% |
| IWP | 99.17M USD | 0.88% |
| IMCG | 8.724M USD | 0.86% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| RMD Tweets |